Fanconi anemia screening

Jump to navigation Jump to search

Fanconi anemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fanconi anemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Fanconi anemia screening On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fanconi anemia screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fanconi anemia screening

CDC on Fanconi anemia screening

Fanconi anemia screening in the news

Blogs on Fanconi anemia screening

Directions to Hospitals Treating Fanconi anemia

Risk calculators and risk factors for Fanconi anemia screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shyam Patel [2]

Overview

There are no recommendations on screening for Fanconi anemia.

Screening

There are no recommendations on screening for Fanconi anemia. Screening for Fanconi anemia is not routinely done during pregnancy. This is in contrast to other disorders such as sickle cell disease or thalassemia, in which robust screening programs are in place. One study in Korea suggested that a nationwide screening program be implemented via treatment of cells with mitomycin C or diepoxybutane, which are DNA damaging agents.[1] However, this study included a very small number of patients and is not universally applicable to other populations. The costs and risks of screening likely outweigh the benefits.

References

  1. Kook H, Cho D, Cho SH, Hong WP, Kim CJ, Park JY; et al. (1998). "Fanconi anemia screening by diepoxybutane and mitomicin C tests in Korean children with bone marrow failure syndromes". J Korean Med Sci. 13 (6): 623–8. doi:10.3346/jkms.1998.13.6.623. PMC 3054538. PMID 9886171.

Template:WH Template:WS